<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>De novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) with dysplastic features in erythroblasts, granulocytes and megakaryocytes, similar to those in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) has been described as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with trilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD) since 1987 </plain></SENT>
<SENT sid="1" pm="."><plain>Several reports have suggested that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD is a subtype of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in adults and has a poor clinical outcome when treated by conventional chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>It is not certain whether allogeneic bone marrow transplantation (BMT) brings a favorable outcome for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD </plain></SENT>
<SENT sid="3" pm="."><plain>To evaluate the therapeutic efficacy of allogeneic BMT for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD, we investigated the clinical data and outcomes of conventional chemotherapy and allogeneic BMT for 118 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>These patients were registered consecutively for the Japan Adult <z:hpo ids='HP_0001909'>Leukemia</z:hpo> Study Group (JALSG) protocols at our institutes </plain></SENT>
<SENT sid="5" pm="."><plain>We treated 28 AML-TLD patients and 90 AML-nonTLD patients with conventional chemotherapeutic protocols </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD patients did not have a significantly different complete remission (CR) rate (75.0% and 88.4% P = 0.1234), but had a significantly higher relapse rate than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-nonTLD patients (94.1% and 49.3%, P= 0.0007) </plain></SENT>
<SENT sid="7" pm="."><plain>The outcome of chemotherapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD was significantly worse than that for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-nonTLD </plain></SENT>
<SENT sid="8" pm="."><plain>The overall survival (OS) and <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) at 6 years were 9.4% and 0% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD group, and 51.9% (P= 0.0017) and 46.3% (P&lt; 0.0001) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-nonTLD group, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Meanwhile, among the patients who underwent allogeneic BMT, five of eight <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD patients and eight of 14 AML-nonTLD patients were alive, and three and five patients survived more than 3 years, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that allogeneic BMT can improve the outcome for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD, which is poor when conventional chemotherapy is given alone </plain></SENT>
<SENT sid="11" pm="."><plain>Allogeneic BMT before relapse may be the best therapeutic strategy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-TLD patients under 50 years of age if a donor is available </plain></SENT>
</text></document>